Drug intelligence / Profile preview

TAK-360

Development stage: Phase 3
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

TAK-360 is an investigational oral small molecule drug developed by Takeda for the treatment of idiopathic hypersomnia and narcolepsy type 2 (narcolepsy without cataplexy). It acts as an agonist of orexin receptor type 2 (OX2R), mimicking the action of orexin, a neuropeptide that regulates wakefulness and alertness. By stimulating OX2R, TAK-360 aims to improve excessive daytime sleepiness in affected individuals. The drug is currently in Phase 1 clinical trials and has received Fast Track designation from the U.S. FDA for these indications[1][2][4][5].

Targets

HCRTR2 (Orexin/hypocretin receptor type 2)

Beyond the preview

Go deeper on TAK-360.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAK-360.

Explore the full profile